Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Somatic mutational landscape reveals mutational signatures and significantly mutated genes of cancer immunotherapeutic outcome and sex disparities.

Frontiers in immunology - 1 Jan 2024

Li Yuting, Wang Qinghua, Gao Xiaopan, Zheng Jinyang, Zhang Wenjing, Ren Yanfeng, Shen Wei, Su Wei, Lu Ping

Abstract excerpt

Background: Currently developed molecular markers can predict the effectiveness of cancer immunotherapy and screen beneficiaries to some extent, but they are not stable enough. Therefore, there is an urgent need for discovering novel biomarkers. At the same time, sex factor plays a vital role in the response to immunotherapy, so it is particularly important to identify sex-related molecular indicators. Methods:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Share to Sex Factors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39555056
DOI: 10.3389/fimmu.2024.1423796
PMCID: PMC11563811

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic mutational landscape reveals mutational signatures and significantly mutated genes of cancer immunotherapeutic outcome and sex disparities.PMID 39555056Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune EvasionSemantic proximity Read ↗

Sex-specific predictive values of biomarkers for immunotherapy efficacy in lung adenocarcinomaSemantic proximity Read ↗

Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias.Semantic proximity Read ↗

Sex-based molecular and prognostic disparities in pan-cancer: an analysis across the global cohorts.Semantic proximity Read ↗

Sex Differences in Cancer Driver Genes and BiomarkersSemantic proximity Read ↗

Cancer-specific associations of driver genes with immunotherapy outcomeSemantic proximity Read ↗

Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients.Semantic proximity Read ↗

Sex differences in oncogenic mutational processes.Semantic proximity Read ↗

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.Semantic proximity Read ↗

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.